IMGN151 for Gynecologic Cancers

This study focuses on evaluating the safety and tolerability of a new investigational drug called IMGN151 for treating gynecologic cancers, which includes cancers like ovarian, uterine, and cervical cancer. The aim is to determine how well IMGN151 works on its own and when combined with other cancer treatments. This research is important because it helps to understand if IMGN151 can be a beneficial option for patients with these types of cancers, potentially offering new treatment avenues and improving patient care. Participants in the study receive IMGN151 through intravenous infusions. They are divided into groups, with each group receiving a different treatment combination or monotherapy. Some groups receive IMGN151 with other drugs like carboplatin, olaparib, or bevacizumab, while others receive it alone. The study lasts about three years, during which participants will regularly visit hospitals or clinics for medical assessments, blood tests, and scans. The study may involve a higher treatment burden compared to standard care, but it aims to gather essential data on the drug's effects and safety.